Top

Journal of Cancer Survivorship

Published in:

01-04-2021 | Stroke

Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study

Authors: Laura C. Pinheiro, Evgeniya Reshetnyak, Monika M. Safford, David Nanus, Lisa M. Kern

Published in: Journal of Cancer Survivorship | Issue 2/2021

Abstract

Purpose

Cardiovascular disease (CVD) is the number one cause of death among 5-year cancer survivors. Survivors see many providers and poor coordination may contribute to worse CVD risk factor control. We sought to determine associations between fragmentation and CVD risk factor control among survivors overall and by self-rated health.

Methods

We included REGARDS participants aged 66+ years who (1) had a cancer history; (2) reported diabetes, hypertension, or hyperlipidemia; and (3) had continuous Medicare coverage. Twelve-month ambulatory care fragmentation was calculated using the Bice-Boxerman Index (BBI). We determined associations between fragmentation and CVD risk factors, defining “control” as fasting glucose < 126 mg/dL or non-fasting glucose < 200 mg/dL for diabetes; blood pressure < 140/90 mmHg for hypertension; and total cholesterol <240 mg/dL, low-density lipoprotein cholesterol < 160 mg/dL, or high-density lipoprotein cholesterol >40 mg/dL for hyperlipidemia.

Results

The 1002 cancer survivors (2+ years since cancer treatment) had mean age of 75 years, 39% were women, and 23% were Black. Among individuals with diabetes (N = 225), hypertension (N = 660), and hyperlipidemia (N = 516), separately, approximately 60% had CVD risk factor control. Overall, more fragmented care was not associated with worse control. However, among cancer survivors with excellent, very good, or good health, more fragmentation was associated with a decreased likelihood of diabetes control (OR 0.78, 95% CI 0.61–0.99), adjusting for confounders.

Conclusions

More fragmented care was associated with worse glycemic control among cancer survivors with diabetes who reported excellent, very good, or good health. Associations were not observed for control of hypertension or hyperlipidemia.

Implications for Cancer Survivors

Reducing fragmentation may support glucose control among survivors with diabetes.

Available only for authorised users

ACS. Life After Cancer: Survivorship by the Numbers: American Cancer Society2014.

ACS. Cancer Facts & Figures 2017. Atlanta, GA: American Cancer Society2017 2017.

Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64. https://doi.org/10.1186/bcr2901.CrossRefPubMedPubMedCentral

Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012;15(1):106–10. https://doi.org/10.1038/pcan.2011.55.CrossRefPubMed

Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533–44. https://doi.org/10.1093/jnci/djk111.CrossRefPubMed

Baade PD, Fritschi L, Eakin EG. Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control. 2006;17(3):287–97. https://doi.org/10.1007/s10552-005-0530-0.CrossRefPubMed

Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–7. https://doi.org/10.1093/annonc/mdw604.CrossRefPubMed

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67. https://doi.org/10.1056/NEJMra1100265.CrossRefPubMed

Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62(2):200–8. https://doi.org/10.1016/0002-9343(77)90315-1.CrossRef

10.

Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612–23. https://doi.org/10.1093/eurheartj/eht114.CrossRefPubMed

11.

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172–87. https://doi.org/10.1056/NEJMra044389.CrossRefPubMed

12.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/nejm200103153441101.CrossRefPubMed

13.

Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–8. https://doi.org/10.1200/jco.2015.62.4718.CrossRefPubMedPubMedCentral

14.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. https://doi.org/10.1161/cir.0000000000000485.CrossRefPubMedPubMedCentral

15.

North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097–108. https://doi.org/10.1161/circresaha.111.246876.CrossRefPubMedPubMedCentral

16.

Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009;27(7):1054–61. https://doi.org/10.1200/jco.2008.18.0950.CrossRefPubMedPubMedCentral

17.

Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712–9. https://doi.org/10.1002/cncr.20560.CrossRefPubMed

18.

IOM. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington, DC: Institute of Medicine2013.

19.

Pinheiro LC, Reshetnyak E, Safford MM, Nanus D, Kern LM. Differences in ambulatory care fragmentation between cancer survivors and noncancer controls. Cancer. 2020;126:3094–101. https://doi.org/10.1002/cncr.32869.CrossRefPubMed

20.

Kern LM, Safford MM, Slavin MJ, Makovkina E, Fudl A, Carrillo JE, et al. Patients’ and providers’ views on causes and consequences of healthcare fragmentation in the ambulatory setting: a qualitative study. J Gen Intern Med. 2019;34(6):899–907. https://doi.org/10.1007/s11606-019-04859-1.CrossRefPubMedPubMedCentral

21.

Hua M, Gong MN, Miltiades A, Wunsch H. Outcomes after rehospitalization at the same hospital or a different hospital following critical illness. Am J Respir Crit Care Med. 2017;195(11):1486–93. https://doi.org/10.1164/rccm.201605-0912OC.CrossRefPubMedPubMedCentral

22.

Romano MJ, Segal JB, Pollack CE. The association between continuity of care and the overuse of medical procedures. JAMA Intern Med. 2015;175(7):1148–54. https://doi.org/10.1001/jamainternmed.2015.1340.CrossRefPubMedPubMedCentral

23.

Tsai TC, Orav EJ, Jha AK. Care fragmentation in the postdischarge period: surgical readmissions, distance of travel, and postoperative mortality. JAMA Surg. 2015;150(1):59–64. https://doi.org/10.1001/jamasurg.2014.2071.CrossRefPubMed

24.

Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135–43. https://doi.org/10.1159/000086678.CrossRefPubMed

25.

Xie F, Colantonio LD, Curtis JR, Safford MM, Levitan EB, Howard G, et al. Linkage of a population-based cohort with primary data collection to Medicare claims: the reasons for geographic and racial differences in stroke study. Am J Epidemiol. 2016;184(7):532–44. https://doi.org/10.1093/aje/kww077.CrossRefPubMedPubMedCentral

26.

Nyweide DJ, Anthony DL, Bynum JP, Strawderman RL, Weeks WB, Casalino LP, et al. Continuity of care and the risk of preventable hospitalization in older adults. JAMA Intern Med. 2013;173(20):1879–85. https://doi.org/10.1001/jamainternmed.2013.10059.CrossRefPubMed

27.

Bice TW, Boxerman SB. A quantitative measure of continuity of care. Med Care. 1977;15(4):347–9.CrossRef

28.

Hussey PS, Schneider EC, Rudin RS, Fox S, Lai J, Pollack CE. Continuity and the costs of care for chronic disease. JAMA Intern Med. 2014;174:742–8.CrossRef

29.

Saultz JW. Defining and measuring interpersonal continuity of care. Ann Fam Med. 2003;1(3):134–43.CrossRef

30.

Jee SH, Cabana MD. Indices for continuity of care: a systematic review of the literature. Med Care Res Rev. 2006;63(2):158–88. https://doi.org/10.1177/1077558705285294.CrossRefPubMed

31.

Pollack CE, Hussey PS, Rudin RS, Fox DS, Lai J, Schneider EC. Measuring care continuity: a comparison of claims-based methods. Med Care. 2013;54:e30–4. https://doi.org/10.1097/MLR.0000000000000018.CrossRef

32.

Assurance NCfQ. HEDIS volume 2: technical specifications. 2015. http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2015.aspx.

33.

Kern LM, Seirup JK, Casalino LP, Safford MM. Healthcare fragmentation and the frequency of radiology and other diagnostic tests: a cross-sectional study. J Gen Intern Med. 2017;32(2):175–81. https://doi.org/10.1007/s11606-016-3883-z.CrossRefPubMed

34.

Liu CW, Einstadter D, Cebul RD. Care fragmentation and emergency department use among complex patients with diabetes. Am J Manag Care. 2010;16(6):413–20.PubMed

35.

Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5–20. https://doi.org/10.2337/diacare.26.2007.s5.

36.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560–72. https://doi.org/10.1001/jama.289.19.2560.CrossRefPubMed

37.

Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama. 2001;285(19):2486–97. https://doi.org/10.1001/jama.285.19.2486.

38.

Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.CrossRef

39.

United Health Foundation U. America’s Health Rankings. 2018. https://www.americashealthrankings.org. . Accessed 12/17/18 2018.

40.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef

41.

Kern LM, Seirup JK, Rajan M, Jawahar R, Stuard SS. Fragmented ambulatory care and subsequent healthcare utilization among Medicare beneficiaries. Am J Manag Care. 2018;24(9):e278–e84.PubMed

42.

Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to health disparities and statin use in the REGARDS (reasons for geographic and racial differences in stroke) study. J Am Heart Assoc. 2017;6(9). https://doi.org/10.1161/jaha.116.005449.

43.

Burgette LF, Reiter JP. Multiple imputation for missing data via sequential regression trees. Am J Epidemiol. 2010;172(9):1070–6. https://doi.org/10.1093/aje/kwq260.CrossRefPubMed

44.

Doove LL, Van Buuren S, Dusseldorp E. Recursive partitioning for missing data imputation in the presence of interaction effects. Comput Stat Data Anal. 2014;72:92–104. https://doi.org/10.1016/j.csda.2013.10.025.CrossRef

45.

Pinheiro LC, Soroka O, Kern LM, Leonard JP, Safford MM. Diabetes care management patterns before and after a cancer diagnosis: a SEER-Medicare matched cohort study. Cancer. 2020;126:1727–35. https://doi.org/10.1002/cncr.32728.CrossRefPubMed

46.

Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? Journal of Cancer Survivorship : research and practice. 2013;7(2):253–61. https://doi.org/10.1007/s11764-013-0267-9.CrossRef

47.

Swiger K. Integration of CVD prevention into Cancer survivorship. Am Coll Cardiol. 2016.

Title: Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study
Authors: Laura C. Pinheiro
Evgeniya Reshetnyak
Monika M. Safford
David Nanus
Lisa M. Kern
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Stroke
Care
Hypertension
Hypertension
Published in: Journal of Cancer Survivorship / Issue 2/2021
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00933-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 2/2021

Health outcomes in offspring born to survivors of childhood cancers following assisted reproductive technologies

A core set of patient-reported outcomes for population-based cancer survivorship research: a consensus study

The impact of scars on health-related quality of life after breast surgery: a qualitative exploration

Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma

Associations between shared care and patient experiences among older cancer survivors

The experiences and needs of couples affected by prostate cancer aged 65 and under: a qualitative study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer